Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H36O4 |
| Molecular Weight | 364.5188 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@]2(C)C\C(C[C@H]12)=C/CCCC(O)=O
InChI
InChIKey=VKPYUUBEDXIQIB-QBPWRKFFSA-N
InChI=1S/C22H36O4/c1-3-4-5-9-17(23)11-12-18-19-13-16(8-6-7-10-21(25)26)14-22(19,2)15-20(18)24/h8,11-12,17-20,23-24H,3-7,9-10,13-15H2,1-2H3,(H,25,26)/b12-11+,16-8-/t17-,18+,19+,20+,22-/m0/s1
| Molecular Formula | C22H36O4 |
| Molecular Weight | 364.5188 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:26 GMT 2025
by
admin
on
Mon Mar 31 18:20:26 GMT 2025
|
| Record UNII |
KZ075BHY4P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C79570
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110886
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
KZ075BHY4P
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
5513
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
6438980
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
81845-44-5
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
100000081523
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
DTXSID901024660
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
C045329
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY | |||
|
SUB07475MIG
Created by
admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|